Author

Zhongyue Yang

Stanford Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Chandrayee GhoshiD· 2 shared Eden Demissie Alamaw· 2 shared Electron KebebewiD· 2 shared Jiangnan HuiD· 2 shared Myriem BoufraqechiD· 2 shared Tejinder Pal KhaketiD· 2 shared Bereketeab HaileselassieiD· 1 shared Maura J. O’NeilliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Chandrayee GhoshORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual targeting of PDPK1 and BRAF V600E is synthetically lethal

Tejinder Pal Khaket, Chandrayee Ghosh, Zhongyue Yang, Myriem Boufraqech, Jiangnan Hu, Eden Demissie Alamaw, Þorkell Andrésson, Maura J. O’Neill, Ya-Qin Zhang, Min Shen, Bereketeab Haileselassie, Electron Kebebew

This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.

bioRxiv · Mar 19, 2026 · PreprintCancer Biology

Dual Targeting of BRAFV600E and Ferroptosis Results in Synergistic Anticancer Activity via Iron Overload and Enhanced Oxidative Stress

Jiangnan Hu, Chandrayee Ghosh, Tejinder Pal Khaket, Zhongyue Yang, Yasmine Tabdili, Eden Demissie Alamaw, Myriem Boufraqech, Scott J. Dixon, Electron Kebebew

This study shows that combining BRAFV600E inhibition with ferroptosis induction synergistically kills anaplastic thyroid cancer cells by increasing iron and oxidative stress.

Journal of Experimental & Clinical Cancer Research · Jan 7, 2026Peer-reviewedCancer Biology